{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:03:27Z","timestamp":1753891407299,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed malignancy and the third leading cause of cancer-related deaths worldwide. A 58-year-old man visited his local hospital due to abdominal discomfort and was diagnosed with lung metastasis. After admission to our hospital in April 2020, he received two cycles of transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC-Folfox), sorafenib, and camrelizumab every 3\u00a0weeks. Due to the end of HAIC treatment, he underwent drug-eluting transcatheter arterial chemoembolization (dTACE) once, sorafenib, and camrelizumab. However, because of worsening liver function, we interrupted TACE and only gave sorafenib and camrelizumab in August 2020. Although he received systemic therapy, the tumors still rapidly progressed and we considered the possibility of tumor resistance. Subsequently, regorafenib was given. In September, the patient underwent conventional TACE (cTACE) once, regorafenib, and camrelizumab. After half a year of comprehensive treatment, the treatment effect was not satisfactory, and he returned to the local hospital to received regorafenib every day and camrelizumab once every 3\u00a0weeks. The patient found that the tumor and lung metastasis had shrunk significantly after 1\u00a0year of the initial diagnosis, then he was admitted to our hospital and received surgery treatment, and now he has survived disease-free for 6\u00a0months.<\/jats:p>","DOI":"10.3389\/fmolb.2021.810251","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T08:09:07Z","timestamp":1643962147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy"],"prefix":"10.3389","volume":"8","author":[{"given":"Qing-Yu","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Lin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Xin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Jun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"B1","first-page":"600","article-title":"Chinese Expert Consensus on Conversion Therapy in Hepatocellular Carcinoma (2021 Edition)","volume":"20","year":"2021","journal-title":"Chin. J. Dig. Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"389","author":"Bruix","year":"2017","journal-title":"The Lancet"},{"key":"B3","first-page":"70","article-title":"Application of Hepatic Arterial Infusion Chemotherapy in the Conversion Therapy of Hepatocellular Carcinoma-Eexperience of Sun Yat-Sen University Cancer Center","volume":"13","author":"Chen","year":"2021","journal-title":"Chin. J. Front. Med. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer Statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA: A Cancer J. Clinicians"},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: a Phase III Randomised, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3348\/kjr.2015.16.3.465","article-title":"2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma","volume":"16","year":"2014","journal-title":"Korean J. Radiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1159\/000439101","article-title":"General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan","volume":"33","author":"Kudo","year":"2015","journal-title":"Dig. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s10637-020-00977-4","article-title":"Real-world Systemic Sequential Therapy with Sorafenib and Regorafenib for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study in Korea","volume":"39","author":"Lee","year":"2021","journal-title":"Invest. New Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2147\/DDDT.S304857","article-title":"Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-cohort of a Multicenter Phase Ib\/II Study","volume":"15","author":"Li","year":"2021","journal-title":"Dddt"},{"key":"B11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00432-010-0868-x","article-title":"An Aggressive Approach Leads to Improved Survival in Hepatocellular Carcinoma Patients with portal Vein Tumor Thrombus","volume":"137","author":"Lin","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6670367","article-title":"Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis","volume":"2021","author":"Liu","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/s0140-6736(03)14964-1","article-title":"Hepatocellular Carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"The Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10637-019-00801-8","article-title":"Sequential Therapy with Sorafenib and Regorafenib for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study in Japan","volume":"38","author":"Ogasawara","year":"2020","journal-title":"Invest. New Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma: a 2017 Update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"B17","first-page":"241","article-title":"Chinese Expert Consensus on Conversion Therapy of Immune Checkpoint Inhibitors Combined Antiangiogenic Targeted Drugs for Advanced Hepatocellular Carcinoma (2021 Edition)","volume":"27","year":"2021","journal-title":"Chin. J. Hepatobiliary Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma: a Multicentre, Open-Label, Parallel-Group, Randomised, Phase 2 Trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40364-021-00319-3","article-title":"Emerging Treatment Modalities for Systemic Therapy in Hepatocellular Carcinoma","volume":"9","author":"Qing","year":"2021","journal-title":"Biomark Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10120-016-0633-1","article-title":"Conversion Therapy for Inoperable Advanced Gastric Cancer Patients by Docetaxel, Cisplatin, and S-1 (DCS) Chemotherapy: a Multi-Institutional Retrospective Study","volume":"20","author":"Sato","year":"2017","journal-title":"Gastric Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A. Cancer J. Clin."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1007\/s10620-007-9808-2","article-title":"Hepatocellular Carcinoma with portal Vein Tumor Thrombosis: Clinical Characteristics, Prognosis, and Patient Survival Analysis","volume":"52","author":"Takizawa","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.2147\/CMAR.S304820","article-title":"Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study","volume":"13","author":"Wei","year":"2021","journal-title":"Cmar"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF\/MEK\/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a New Oral Multikinase Inhibitor of Angiogenic, Stromal and Oncogenic Receptor Tyrosine Kinases with Potent Preclinical Antitumor Activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/j.1572-0241.2005.00229.x","article-title":"Natural History of Untreated Nonsurgical Hepatocellular Carcinoma","volume":"100","author":"Yeung","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"12683","DOI":"10.2147\/OTT.S286169","article-title":"Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study","volume":"13","author":"Yuan","year":"2020","journal-title":"Ott"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.810251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T08:09:14Z","timestamp":1643962154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.810251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":27,"alternative-id":["10.3389\/fmolb.2021.810251"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.810251","relation":{},"ISSN":["2296-889X"],"issn-type":[{"type":"electronic","value":"2296-889X"}],"subject":[],"published":{"date-parts":[[2022,2,4]]},"article-number":"810251"}}